Second Failure Knocks Argenx’s Vyvgart Blockbuster Expansion Plans
A Phase III study may have been scuppered by its design, but Argenx remains confident that Vyvgart will still be an autoimmune disease 'pipeline in a product'.
A Phase III study may have been scuppered by its design, but Argenx remains confident that Vyvgart will still be an autoimmune disease 'pipeline in a product'.